Association of gliclazide and left ventricular mass in type 2 diabetic patients

Diabetes Research and Clinical Practice
Nan-Hung PanNen-Chung Chang

Abstract

Diabetes is a state of increased oxidant stress and there is evidence that oxidation may play a role in the genesis of higher left ventricular mass. Gliclazide has been shown to possess free radical scavenging properties. We assessed whether gliclazide may have a beneficial effect on left ventricular mass via reducing 8-iso-prostaglandin F(2alpha) concentrations, a reliable marker of oxidant injury. A total of 41 patients were randomized into two groups. All patients had been taking glibenclamide for more than 3 months before being randomized to switch either an equipotent dose of gliclazide (n=21) or to continue on glibenclamide (n=20). Baseline characteristics were similar in both groups. At 6 months, gliclazide-treated patients showed a significant regression in left ventricular mass index compared with the glibenclamide-treated group (-16% versus 3%, P=0.003). Gliclazide patients had significantly lower plasma 8-iso-prostaglandin F(2alpha) compared with baseline (299+/-101 pg/ml versus 400+/-112 pg/ml, P=0.001) and the glibenclamide-treated patients (299+/-101 pg/ml versus 388+/-114 pg/ml, P=0.01) after 6-month therapy. The magnitude of left ventricular mass index regression correlated univariately with the magnitude of inh...Continue Reading

References

Feb 15, 1986·The American Journal of Cardiology·R B DevereuxN Reichek
Jan 3, 1994·Biochimica Et Biophysica Acta·J D MorrowL J Roberts
Jan 12, 1996·The Journal of Biological Chemistry·J W AdamsS A Henderson
Mar 1, 1996·Diabetes Care·D GiuglianoG Paolisso
Sep 1, 1996·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·K GeisenJ G Papp
Dec 31, 1997·Arteriosclerosis, Thrombosis, and Vascular Biology·G DaviC Patrono
Feb 29, 2000·Metabolism: Clinical and Experimental·Y NodaL Packer
Jun 29, 2000·Journal of Hypertension·N S DhallaT Netticadan
Feb 20, 2002·Journal of Molecular and Cellular Cardiology·Yoshiharu HiguchiMasatsugu Hori
Feb 28, 2002·The Journal of Pharmacology and Experimental Therapeutics·Victoria C TuQin M Chen
Oct 2, 2003·Journal of Molecular and Cellular Cardiology·Michael R MorissetteJoan Heller Brown
Jan 8, 2004·Clinical Chemistry and Laboratory Medicine : CCLM·Edzard Schwedhelm, Rainer H Böger
Feb 12, 2004·Kidney International·Maristela Lika OnozatoToshiro Fujita

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomegaly

Cardiomegaly, known as an enlarged heart, is a multifactorial disease with different pathophysiological mechanisms. Hypertension, pregnancy, exercise-induced and idiopathic causes are some mechanisms of cardiomegaly. Discover the latest research of cardiomegaly here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.